Red River West — Deep Research Brief for Feb 17 Call
Company Overview
- Type: Transatlantic VC fund (Paris/LA)
- Focus: European tech/biotech startups targeting US expansion
- Strategic Partners: Matthieu Bucaille, Yves Sisteron (joined May 2024) — expertise in VC, M&A, US expansion
- Website: redriverwest.com
Key Portfolio Companies (Health/Pharma Relevant)
| Company | Focus | Latest Raise | Status |
|---|---|---|---|
| Ada Health | AI symptom checking | — | Pfizer partnership active; 6+ pharma deals |
| Okeiro | Precision medicine (transplant/chronic) | €10M (RRW led) | US market entry 2026 |
| MaaT Pharma | Microbiome cancer immunotherapy | €9.1M | Xervyteg® decision mid-2026; FDA US pivotal 2026 |
| Resilience | Remote cancer monitoring | $25M | Germany expansion + clinical trial platform |
Antoine — Contact History
- 5 past calls with Daniel
- Last interaction: Nov 21, 2025
- ~3 month gap since last contact
- Deal stage: Advanced
Conversation Strategy
Frame: "What's changed in your portfolio since November — especially Okeiro's US entry and MaaT's FDA path?" Key Questions:- How is Okeiro's US market entry progressing? What's the go-to-market?
- MaaT FDA engagement — any early signals on pathway?
- Where does RRW see the biggest gap in their health portfolio?
- Are they raising a new fund or deploying from current?
- What does a pilot/partnership with us look like from their side?